In Vivo Evaluation of Recombinantly Expressing M-Cell-Targeting Co1 Peptide Fused with VP1 of Enterovirus A71 Capsid

Ngo-My, Tien; Nguyen-Le, Duy; Le, Truong-Thang; Mai, Quoc-Gia; Vo-Nguyen, Hai-Vy; Nguyen, Anh-Huy Ngoc; Dao, Khanh-Linh Thi; Quang, Kiep Thi; Vu, Huyen-Trang Thi; Nguyen, Thanh-Thao Thi; Tran-Van, Hieu

doi:10.1007/s40995-023-01489-5

Iran J Sci

2023

DOI: 10.1007/s40995-023-01489-5

|View full text |Cite

In Vivo Evaluation of Recombinantly Expressing M-Cell-Targeting Co1 Peptide Fused with VP1 of Enterovirus A71 Capsid

Tien Ngo-My,

Duy Nguyen-Le,

Truong-Thang Le

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

An Oral Nanovaccine Secreted by Genetically Engineered and Ultrasound‐Responsive Bacteria for Colon Cancer Immunotherapy

Li,

Yang,

Yuan

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Colorectal cancers represent a major global morbidity and mortality burden, neccessitating improved treatment paradigms. In this work, an ingestible, genetically engineered Escherichia coli (E. coli) 1917 termed “E. coli (AH1‐CDA‐Co1)” is designed that upon ultrasound exposure secretes bacterial outer membrane vesicles (OMV) incorporating the AH1 tumor rejection epitope, an enzyme producing the stimulator of interferon genes (STING) agonist CDA, and the microfold cell‐targeting peptide Co1. For oral administration, a polydopamine system (iPDA) coating on bacteria is exploited to resist the acidic condition in stomach, increase the bacterial survival, and prolong the intestinal transit time. Upon harmless ultrasound exposure, sustained secretion of engineered OMV vaccines is triggered that efficiently cross the intestinal epithelium. Both cyclic GMP–AMP synthase (cGAS)‐STING and TLR4 innate immune signaling pathways are activated, triggering long‐term antigen‐specific immune responses that overcome the immunosuppressive tumor microenvironment. In subcutaneous and orthotopic murine colorectal tumor models, the E. coli (AH1‐CDA‐Co1)@iPDA system inhibits tumor growth and prolongs survival without recurrence. E. coli (AH1‐CDA‐Co1)@iPDA also inhibits tumor growth and recurrence in a postoperative orthotopic colonrectal tumor model of lymph node metastases. Taken together, E. coli (AH1‐CDA‐Co1)@iPDA demonstrates a potent oral vaccine system for improved colon cancer immunotherapy.

show abstract

An Oral Nanovaccine Secreted by Genetically Engineered and Ultrasound‐Responsive Bacteria for Colon Cancer Immunotherapy

Li,

Yang,

Yuan

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

In Vivo Evaluation of Recombinantly Expressing M-Cell-Targeting Co1 Peptide Fused with VP1 of Enterovirus A71 Capsid

Cited by 1 publication

References 22 publications

An Oral Nanovaccine Secreted by Genetically Engineered and Ultrasound‐Responsive Bacteria for Colon Cancer Immunotherapy

An Oral Nanovaccine Secreted by Genetically Engineered and Ultrasound‐Responsive Bacteria for Colon Cancer Immunotherapy

Contact Info

Product

Resources

About